ENDPOINTS

Novartis to buy Regulus Therapeutics for up to $1.7B

Novartis plans to acquire Regulus Therapeutics for $7.00 per share in cash, or $800 million, the microRNA specialist said Wednesday. This is more than double Regulus’ share price at Tuesday’s close ...

Apr 30, 2025 - 12:38
 0
Novartis to buy Regulus Therapeutics for up to $1.7B
Novartis plans to acquire Regulus Therapeutics for $7.00 per share in cash, or $800 million, the microRNA specialist said Wednesday. This is more than double Regulus’ share price at Tuesday’s close ...
Read More

Tags:

Previous Article

Why Ozempic and Wegovy Might Change Your Favorite Food

Next Article

How we call out the infuriating mistakes we spot in school science textbooks

Related Posts

Endpoints Slack interview: Arc Institute's Patrick Hsu on AI bio, investing

Endpoints Slack interview: Arc Institute's Patrick Hsu ...

Apr 30, 2025  0

AstraZeneca, Daiichi eye first-line breast cancer market after Enhertu's early Phase 3 win

AstraZeneca, Daiichi eye first-line breast cancer marke...

Apr 22, 2025  0

Regeneron to boost its US manufacturing through a $3B Fujifilm deal

Regeneron to boost its US manufacturing through a $3B F...

Apr 22, 2025  0